NCT04222231Completed
RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes
Metabolic Effects of a New Resistance Training in Individuals With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
The study aims to investigate the metabolic and cardiovascular effects of classical resistance training with high loads and blood-flow restricted training (BFRT) with low loads in individuals with type 2 diabetes over 12 weeks.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 10 Dec 2019
- Start date
- 28 Oct 2019
- Primary completion date
- 1 May 2024
- Lead sponsor
- German Diabetes Center
- Diseases
- Type 2 diabetes
- NCT number
- NCT04222231
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 28 Oct 2019 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Therapy with Glitazone, Beta blocker, Insulin
- Thyroid disease (untreated hypothyroidism or hyperthyroidism, treatment with thiamazol)
- Application of drugs which can manipulate the thermoregulation (Antipsychotic)
- Cigarettes (or non-smokers <1 year) alcohol consumption (men> 30 g / d, women> 20 g / d), drug abuse
Other illness
- Acute infections in the last 2 weeks
- Malignant cancer
- Heart diseases (angina pectoris, myocardial infarction, acute myocarditis or pericarditis, cardiac wall aneurysms/ stenose, untreated hypotension or hypertension, aortic stenosis, stroke, cardiac insufficiency, NYHA-class ≥II, heart arrhythmia, disturbances of blood circulation in extremities, venous insufficiency, varicose veins)
- Respiratory disease (COPD, Gold grade ≥II)
- Disease of the immune system (leucocytes <5000/μl)
- Epilepsy
- Severe psychiatric illness or addiction
- Risk for/ or HIV or Hepatitis B or C
- Muscle diseases, orthopedic restrictions
- Hypersensitivity to local anaesthetic
- Metallic and magnetic implants (for example, mechanical heart valves, joint prostheses, clip after vascular surgery, middle and inner ear implants or fresh dental implants)
Lab values
- Serious heart, kidney or liver disease: - New York Heart Association-Classification (NYHA) stage ≥ II - creatinine ≥ 1.6 mg / dl - Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ two-fold upper reference value
- Blood clotting disorders (abnormally levels of thrombocytes [<150.000, >450.000 ± 50 ], Partial thromboplastin time (PTT) [26-36 s ± 5 s], Quick [70-120% ± 10%]) or wound healing
Other
- Weight fluctuations (> 10% in the last 6 month)
- Diabetic neuropathy
- Anemia (Hb <12g / l), blood donation in the last 3 month
- Application of immunomodulatory agents (Glucocorticoids, Antihistamine, Acetylsalicylic acid)
- Application of antithrombotic agents (Anticoagulant)
- Rosacea
- Vitamine supplement (with the las 4 weeks)
- Shift work or anormal circadian rhythm
- Pregnancy, lactation
- Claustrophobia
- Hypohidrosis
- Participation in another intervention study within the last 3 month
Who the study is looking for
- Male and female, age between ≥ 30 and ≤ 69 years
- Individuals with type 2 diabetes
- BMI: 19-40 kg/m²
Age in the registry: 30 years to 69 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| German Diabetes Center Coordinator of this site? Confirm its status | Düsseldorf | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.